Heart failure & cardiomyopathies
Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre
Authors' conclusion
Our real-world experience aligns with established mavacamten trial outcomes.
Study context
- Population
- Patients with symptomatic obstructive hypertrophic cardiomyopathy (left ventricular outflow tract obstruction (LVOTO) gradient >50 mmHg, New York Heart Association (NYHA) class ≥II despite maximally tolerated therapy, left ventricular ejection fraction (LVEF) >55%), March–November 2023
- Participants
- 31 patients
- Outcome
- Change in mean provoked LVOT gradient
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Reduction in mean provoked left ventricular outflow tract gradient (LVOTG) at 4 weeks
−49.4 mmHg
P < 0.001
Reduction in mean provoked LVOTG at 8 weeks
−59.2 mmHg
P < 0.001
Reduction in mean provoked LVOTG at 12 weeks
−60.8 mmHg
P < 0.001
Observational data: associations, not effects.
Further findings
LVOTG ≤30 mmHg · Week 12
- Patients achieving LVOTG ≤30 mmHg
- 26 of 31 (83.8%)
NYHA class improvement ≥2 classes
- ≥2 NYHA class improvements
- 67%
Safety
- No major side effects reported
- LVEF remained above 55%
- No dose titration was made
Original publication
Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre. ESC Heart Fail. Published 13 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →